IKAP Stock Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aurinia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.46 |
| 52 Week High | US$11.20 |
| 52 Week Low | US$4.43 |
| Beta | 1.38 |
| 1 Month Change | -4.43% |
| 3 Month Change | -38.36% |
| 1 Year Change | -53.27% |
| 3 Year Change | -56.52% |
| 5 Year Change | -19.10% |
| Change since IPO | -27.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| IKAP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.5% | -4.9% | -1.5% |
| 1Y | -53.3% | -19.9% | 0.9% |
Return vs Industry: IKAP underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: IKAP underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| IKAP volatility | |
|---|---|
| IKAP Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IKAP's share price has been volatile over the past 3 months.
Volatility Over Time: IKAP's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 300 | Peter Greenleaf | www.auriniapharma.com |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.
Aurinia Pharmaceuticals Inc. Fundamentals Summary
| IKAP fundamental statistics | |
|---|---|
| Market cap | €667.11m |
| Earnings (TTM) | -€73.30m |
| Revenue (TTM) | €164.89m |
4.0x
P/S Ratio-9.1x
P/E RatioIs IKAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IKAP income statement (TTM) | |
|---|---|
| Revenue | US$175.51m |
| Cost of Revenue | US$21.68m |
| Gross Profit | US$153.83m |
| Other Expenses | US$231.85m |
| Earnings | -US$78.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 87.65% |
| Net Profit Margin | -44.45% |
| Debt/Equity Ratio | 0% |
How did IKAP perform over the long term?
See historical performance and comparison